Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its Tecnis PureSee intraocular lens (IOL), giving eye surgeons a new lens option for use in ...

The TECNIS Odyssey IOL addresses a significant unmet need for cataract patients seeking greater spectacle independence., Bizz ...

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

The Conversation reports cataract surgery is safe and common, with over 90% achieving 20/20 vision, but patients need to ...

Johnson & Johnson (NYSE:JNJ) received FDA approval for its TECNIS PureSee IOL, an extended depth of focus intraocular lens ...

The global intraocular lens market is experiencing sustained momentum driven by the increasing prevalence of cataracts, growing adoption of premium and multifocal lenses, and continuous advances in ...

My New York City practice has been a refractive-only practice for more than 25 years, offering the full range of FDA-approved ...

Enhancement coverage applies within 24 months of the original procedure for refractive and premium lens pathways. Beyond this ...

The purpose of this study was to compare the surgical outcomes of intraocular lens (IOL) refixation with intraocular lens exchange using perfluorocarbon liquid (PFCL) and fibrin glue-assisted ...

These studies found that IOL implant errors were due to intraoperative errors including failure to check the lens specifications, a lack of procedure for verification of the correct lens, confusion of ...

The purpose of this study was to determine the long-term complications and outcomes of secondary intraocular lens (IOL) implantation in patients with congenital cataracts. The medical records of ...